Macro Genics Inc - Understand $mgnx stock

$MGNX Market Cap: $273 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$141.3M

TTM

Gross Margin

98.43%

TTM

Net Earnings

-$97.62M

TTM

Current Assets

$222.2M

Q3 2024

Current Liabilities

$59.31M

Q3 2024

Current Ratio

374.64%

Q3 2024

Total Assets

$264.5M

Q3 2024

Total Liabilities

$144.4M

Q3 2024

Book Value

$120.1M

Q3 2024

Cash

$179.6M

Q3 2024

P/E

-2.797

Nov 08, 2024 EST

Free Cash Flow

-$61.71M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$58.75M	$151.9M	$77.45M	$104.9M	$64.19M	$60.12M	$157.7M	$91.88M	$100.9M	$47.80M	$58.04M	$63.83M	$57.21M
YoY Change	-61.33%	96.19%	-26.16%	63.4%	6.76%	-61.89%	71.68%	-8.9%	111.0%	-17.64%	-9.07%	11.57%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$58.75M	$151.9M	$77.45M	$104.9M	$64.19M	$60.12M	$157.7M	$91.88M	$100.9M	$47.80M	$58.04M	$63.83M	$57.21M
Cost Of Revenue	$8.222M	$3.351M	$2.651M	$0.00	$0.00
Gross Profit	$50.53M	$148.6M	$74.80M	$104.9M	$64.19M
Gross Profit Margin	86.0%	97.79%	96.58%	100.0%	100.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$52.19M	$58.95M	$63.01M	$42.70M	$46.10M	$40.50M	$32.70M	$29.80M	$22.80M	$15.90M	$11.10M	$10.20M	$10.90M
YoY Change	-11.47%	-6.45%	47.57%	-7.38%	13.83%	23.85%	9.73%	30.7%	43.4%	43.24%	8.82%	-6.42%
% of Gross Profit	103.29%	39.67%	84.25%	40.71%	71.82%
Research & Development	$166.6M	$207.0M	$214.6M	$193.2M	$195.3M	$190.8M	$147.2M	$122.1M	$98.27M	$70.19M	$46.58M	$45.43M	$41.09M
YoY Change	-19.54%	-3.52%	11.06%	-1.08%	2.35%	29.61%	20.59%	24.24%	40.02%	50.67%	2.53%	10.57%
% of Gross Profit	329.69%	139.33%	286.88%	184.21%	304.28%
Depreciation & Amortization	$9.645M	$11.87M	$11.26M	$11.96M	$12.31M	$9.160M	$7.228M	$7.608M	$2.863M	$1.822M	$1.200M	$1.000M	$1.100M
YoY Change	-18.71%	5.39%	-5.85%	-2.84%	34.34%	26.73%	-4.99%	165.74%	57.14%	51.83%	20.0%	-9.09%
% of Gross Profit	19.09%	7.99%	15.05%	11.4%	19.17%
Operating Expenses	$218.8M	$207.0M	$214.6M	$193.2M	$195.3M	$190.8M	$147.2M	$122.1M	$98.27M	$70.19M	$46.58M	$45.43M	$41.09M
YoY Change	5.67%	-3.52%	11.06%	-1.08%	2.35%	29.61%	20.59%	24.24%	40.02%	50.67%	2.53%	10.57%
Operating Profit	-$168.2M	-$121.4M	-$202.8M	-$131.1M	-$177.2M	-$171.2M	-$22.14M	-$60.04M	-$20.18M	-$38.32M	$366.0K	$8.205M	$5.250M
YoY Change	38.57%	-40.13%	54.73%	-26.03%	3.49%	673.18%	-63.12%	197.5%	-47.33%	-10568.58%	-95.54%	56.3%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$2.569M	$1.700M	$2.000M	$800.0K								$0.00	$0.00
YoY Change	51.12%	-15.0%	150.0%
% of Operating Profit												0.0%	0.0%
Other Income/Expense, Net	$5.686M	$1.660M	$680.0K	$1.321M	$25.37M	-$247.0K	$2.517M	$1.514M	$42.00K	$2.000K	-$627.0K	$157.0K	$1.467M
YoY Change	242.53%	144.12%	-48.52%	-94.79%	-10372.87%	-109.81%	66.25%	3504.76%	2000.0%	-100.32%	-499.36%	-89.3%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$9.059M	-$119.8M	-$202.1M	-$129.7M	-$151.8M	-$171.5M	-$19.60M	-$58.50M	-$20.10M	-$38.30M	-$300.0K	$8.400M	$6.700M
YoY Change	-92.44%	-40.75%	55.83%	-14.56%	-11.49%	775.0%	-66.5%	191.04%	-47.52%	12666.67%	-103.57%	25.37%
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income												0.0%
Net Earnings	-$9.058M	-$119.8M	-$202.1M	-$129.7M	-$151.8M	-$171.5M	-$19.63M	-$58.53M	-$20.14M	-$38.31M	-$261.0K	$8.362M	$6.717M
YoY Change	-92.44%	-40.75%	55.79%	-14.54%	-11.46%	773.6%	-66.47%	190.61%	-47.43%	14579.31%	-103.12%	24.49%
Net Earnings / Revenue	-15.42%	-78.82%	-260.97%	-123.7%	-236.51%	-285.18%	-12.44%	-63.7%	-19.97%	-80.16%	-0.45%	13.1%	11.74%
Basic Earnings Per Share	-$0.15	-$1.95	-$3.37	-$2.47						-$1.40	-$0.04	$0.00	$0.00
Diluted Earnings Per Share	-$0.15	-$1.95	-$3.372M	-$2.475M	-$3.156M	-$4.193M	-$542.9K	-$1.686M	-$632.1K	-$1.40	-$0.04	$0.00	$0.00

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$229.8M	$154.3M	$243.6M	$272.5M	$215.8M	$232.9M	$305.1M	$277.0M	$339.0M	$157.6M	$116.5M	$47.70M	$55.20M
YoY Change	48.89%	-36.64%	-10.6%	26.27%	-7.34%	-23.66%	10.14%	-18.29%	115.1%	35.28%	144.23%	-13.59%
Cash & Equivalents	$101.0M	$108.9M	$123.5M	$181.1M	$126.5M	$220.1M	$211.7M	$84.10M	$196.2M	$157.6M	$116.5M	$47.70M	$55.20M
Short-Term Investments	$128.8M	$45.46M	$120.1M	$91.40M	$89.30M	$12.70M	$93.40M	$192.9M	$142.9M
Other Short-Term Assets	$9.946M	$10.16M	$21.17M	$17.00M	$11.30M	$6.700M	$3.600M	$4.200M	$2.100M	$4.200M	$1.000M	$100.0K	$0.00
YoY Change	-2.12%	-52.0%	24.53%	50.44%	68.66%	86.11%	-14.29%	100.0%	-50.0%	320.0%	900.0%
Inventory	$1.221M	$1.451M	$4.388M
Prepaid Expenses
Receivables	$10.37M	$56.22M	$10.39M	$23.10M	$12.70M	$29.60M	$13.60M	$2.800M	$1.200M	$2.900M	$2.000M	$2.000M	$3.400M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$251.3M	$222.2M	$279.6M	$312.6M	$239.8M	$269.1M	$322.3M	$283.9M	$342.4M	$164.7M	$119.5M	$49.90M	$58.70M
YoY Change	13.12%	-20.53%	-10.57%	30.36%	-10.89%	-16.51%	13.53%	-17.09%	107.89%	37.82%	139.48%	-14.99%
Property, Plant & Equipment	$45.69M	$56.91M	$54.28M	$61.40M	$48.20M	$56.70M	$50.00M	$18.00M	$14.80M	$6.800M	$5.000M	$3.300M	$3.300M
YoY Change	-19.71%	4.85%	-11.6%	27.39%	-14.99%	13.4%	177.78%	21.62%	117.65%	36.0%	51.52%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments							$0.00	$8.000M	$0.00
YoY Change							-100.0%
Other Assets	$1.386M	$1.378M	$1.409M	$4.700M	$24.50M	$6.300M	$1.600M	$1.400M	$2.000M	$2.400M	$1.300M	$600.0K	$700.0K
YoY Change	0.58%	-2.2%	-70.02%	-80.82%	288.89%	293.75%	14.29%	-30.0%	-16.67%	84.62%	116.67%	-14.29%
Total Long-Term Assets	$47.08M	$58.29M	$55.69M	$66.10M	$72.70M	$63.00M	$51.60M	$27.40M	$16.90M	$9.200M	$6.300M	$3.800M	$4.000M
YoY Change	-19.23%	4.67%	-15.76%	-9.08%	15.4%	22.09%	88.32%	62.13%	83.7%	46.03%	65.79%	-5.0%
Total Assets	$298.4M	$280.5M	$335.2M	$378.7M	$312.5M	$332.1M	$373.9M	$311.3M	$359.3M	$173.9M	$125.8M	$53.70M	$62.70M
YoY Change
Accounts Payable	$6.443M	$4.899M	$15.50M	$8.000M	$4.300M	$4.000M	$2.500M	$4.000M	$3.000M	$1.700M	$3.200M	$3.700M	$11.10M
YoY Change	31.52%	-68.39%	93.75%	86.05%	7.5%	60.0%	-37.5%	33.33%	76.47%	-46.88%	-13.51%	-66.67%
Accrued Expenses	$28.01M	$33.72M	$38.43M	$38.20M	$30.20M	$33.00M	$38.60M	$16.10M	$11.70M	$7.900M	$3.600M	$1.200M	$1.100M
YoY Change	-16.93%	-12.25%	0.61%	26.49%	-8.48%	-14.51%	139.75%	37.61%	48.1%	119.44%	200.0%	9.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due							$300.0K	$1.600M	$2.000M	$1.600M	$1.400M	$600.0K	$500.0K
YoY Change							-81.25%	-20.0%	25.0%	14.29%	133.33%	20.0%
Total Short-Term Liabilities	$56.11M	$48.61M	$74.58M	$50.70M	$45.20M	$59.90M	$49.80M	$27.30M	$24.20M	$27.10M	$28.80M	$29.70M	$44.30M
YoY Change	15.42%	-34.82%	47.1%	12.17%	-24.54%	20.28%	82.42%	12.81%	-10.7%	-5.9%	-3.03%	-32.96%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$300.0K	$2.700M	$6.400M	$0.00	$9.400M	$10.10M
YoY Change							-100.0%	-88.89%	-57.81%		-100.0%	-6.93%
Other Long-Term Liabilities	$89.70M	$89.84M	$21.05M	$32.20M	$36.70M	$29.30M	$24.90M	$14.90M	$19.00M	$19.10M	$18.00M	$22.80M	$25.80M
YoY Change	-0.16%	326.83%	-34.63%	-12.26%	25.26%	17.67%	67.11%	-21.58%	-0.52%	6.11%	-21.05%	-11.63%
Total Long-Term Liabilities	$89.70M	$89.84M	$21.05M	$32.20M	$36.70M	$29.30M	$24.90M	$15.20M	$21.70M	$25.50M	$18.00M	$32.20M	$35.90M
YoY Change	-0.16%	326.83%	-34.63%	-12.26%	25.26%	17.67%	63.82%	-29.95%	-14.9%	41.67%	-44.1%	-10.31%
Total Liabilities	$145.8M	$138.5M	$95.63M	$82.90M	$81.90M	$89.30M	$74.60M	$42.50M	$45.90M	$52.60M	$46.90M	$62.00M	$80.20M
YoY Change	5.31%	44.79%	15.35%	1.22%	-8.29%	19.71%	75.53%	-7.41%	-12.74%	12.15%	-24.35%	-22.69%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2017	2016	2015	2014	2013	2012	2011
Basic Shares Outstanding	61.93M shares	61.43M shares	59.94M shares	52.44M shares	48.08M shares	36.10M shares	34.69M shares	31.80M shares	27.38M shares	6.848M shares	1.083M shares	1.026M shares
Diluted Shares Outstanding	61.93M shares	61.43M shares	59.94M shares	52.44M shares	48.08M shares	36.10M shares	34.69M shares	31.80M shares	27.38M shares	6.848M shares	1.083M shares	1.026M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $273.02 Million

About MacroGenics Inc

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 339 full-time employees. The company went IPO on 2013-10-10. The company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. The company is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. The company is also developing various other programs.

Industry: Pharmaceutical Preparations Peers: Lineage Cell Therapeutics Inc /entities/grtsq Kronos Bio Inc LianBio Rigel Pharmaceuticals Inc Shuttle Pharmaceuticals Holdings Inc Viking Therapeutics Inc XOMA Royalty Corp